NCT05636228

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Patients With Acute Infectious Keratoconjunctivitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Invirsa, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.

Conditions

• Acute Infectious Keratoconjunctivitis

Interventions

Type	Name	Description
DRUG	INV-102	INV-102 Ophthalmic Solution
DRUG	Vehicle	Vehicle Ophthalmic Solution

Timeline

• Start date: 2023-06-09
• Primary completion: 2024-08-22
• Completion: 2024-08-22
• First posted: 2022-12-05
• Last updated: 2025-08-22

Locations

12 sites across 2 countries: United States, Thailand

Regulatory

• FDA-regulated drug study